You searched for "sinus"
Study flags evidence gaps in AI eye imaging devices approved for patient care
Uneven evidence and poor data transparency revealed in review of AI as a medical device. A review of regulator-approved medical AI models in eye care has found that they vary widely in providing evidence for clinical performance and lacked transparency...Innovations in posterior uveitis: In conversation with Dr Colin Chu
1 July 2025
| Colin Chu
|
EYE - Imaging
A research team has been awarded significant funding by the National Institute for Health and Care Research (NIHR) to develop an innovative drug-device combination that aims to revolutionise how individual immune cells are monitored and treated in patients at Moorfields...
The art of ophthalmic simulations
4 December 2023
| Nicky L Webster
|
EYE - Imaging
For Dec/Jan 2024, I got in touch with Nicky Webster, a Principal 3D Artist at FundamentalVR (https://fundamentalsurgery.com). Nicky is also a registered medical illustrator, healthcare scientist and medical photographer. With over 18 years of experience working in various disciplines within...
Could the sclera be key to glaucoma?
1 December 2017
| Craig Boote
|
EYE - Glaucoma
The glaucomas are a group of conditions characterised by optic neuropathy and associated visual field defects. Of these, chronic open-angle glaucoma (COAG) – diagnosed on the basis of progressive structural changes to the optic nerve head (ONH) and nerve fibre...
Eye Capacity: clinical need should drive ophthalmic service provision
1 February 2014
| Rod McNeil
Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...
Neovascular AMD: fresh recommendations underline standards of best practice
1 December 2013
| Rod McNeil
The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...
Macular holes: A brief review
1 August 2017
| Sidath Wijetilleka, Roger McPherson
|
EYE - Vitreo-Retinal
The classification of macular holes has been modernised by OCT findings. This is a brief review and encompasses the historical literature on macular holes. A macular hole is an anatomical discontinuation of the neurosensory retina at the centre of the...
Toxoplasmosis and the associated retinochoroiditis: important facts and when to treat
1 April 2017
| Annie SeeWah Tung
|
EYE - Vitreo-Retinal
Annie SeeWah Tung provides an overview of toxoplasmosis retinochoroiditis, including guidance on which cases should be treated and the treatment options. Toxoplasmosis retinochoroiditis is an infectious condition that is characterised by retinochoroidal lesions commonly in the posterior pole and is...
Retinoblastoma management update (part 1): clinical features, diagnosis and genetics
1 January 2017
| Manoj V Parulekar
|
EYE - Oncology
The first of a two part series, this article will discuss the clinical features, diagnosis and genetic aspects of retinoblastoma. Manoj Parulekar is based at Birmingham Children’s Hospital, one of the two designated national retinoblastoma and paediatric ocular oncology treatment...
Addressing medical risk factors for diabetes and understanding the new systemic treatments
1 February 2014
| Samantha S Mann
As global diabetes figures continue to rise, the importance of reducing the burden of macrovascular and microvascular complications of diabetes has never been so great. By 2025 it is estimated that five million people in the UK will have diabetes...
Corporate M&A pace gathers momentum
1 October 2019
| Rod McNeil
|
EYE - General
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...
